The Appointments Committee of the Cabinet has approved the appointment of Rajeev Raghuvanshi as the new Drug Controller General of India (DCGI).

Raghuvanshi, who is currently the Secretary-cum-Scientific Director at Indian Pharmacopoeia Commission, has been given the DCGI charge for a three-year period ending on February 28, 2025.

A Senior Executive with proven track record in leading Indian Pharmaceutical industry, he has demonstrated the capability of establishing, growing and taking R & D organisations to next level.

He is experienced in generics, nanotechnology, innovative platform technologies, open innovation, out sourcing, cost cutting, lean development, international and national collaborations.

He has served as the Senior Vice President and Head, Differentiated Formulations R & D / BRaIN at Dr. Reddy's; Director at Ranbaxy Research Laboratories; Scientist at the National Institute of Immunology; and Research Associate, Formulation Development at Dabur Research Foundation

Raghuvanshi will be replacing PBN Prasad, who was given an interim charge of DCGI up until now. Prasad had replaced V G Somani, whose three-year tenure had expired in August last year. He was, however, given two extensions of three months each.